American Journal of Obstetrics & Gynecology
Volume 197, Issue 4 , Pages 340-345 , October 2007

2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ

  • Thomas C. Wright Jr, MD

      Affiliations

    • Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY
    • Corresponding Author InformationReprints: Thomas C. Wright Jr, MD, Department of Pathology, College of Physicians and Surgeons of Columbia University, Room 16-404, P&S Building, 630 West 168th St, New York, NY 10032
    • ,
  • L. Stewart Massad, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, MO
    • ,
  • Charles J. Dunton, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Lankenau Hospital, Wynnewood, PA
    • ,
  • Mark Spitzer, MD

      Affiliations

    • Department of Obstetrics and Gynecology, Brookdale University Hospital and Medical Center, Brooklyn, NY
    • ,
  • Edward J. Wilkinson, MD

      Affiliations

    • Department of Pathology, University of Florida College of Medicine, Gainesville, FL
    • ,
  • Diane Solomon, MD

      Affiliations

    • National Institutes of Health and National Cancer Institute, Bethesda, MD.
    • ,
  • 2006 American Society for Colposcopy and Cervical Pathology–sponsored Consensus Conference

Received 6 April 2007 ,Revised 28 June 2007 ,Accepted 29 July 2007.

References 

  1. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004;128:1224–1229
  2. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–113
  3. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120–2129
  4. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188:1383–1392
  5. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol. 2003;188:1393–1400
  6. Wright TC, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007;197:346–355
  7. Martin-Hirsch PL, Paraskevaidis E, Kitchener H. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2000;CD001318
  8. Kyrgiou M, Tsoumpou I, Vrekoussis T, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy and cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev. 2006;32:516–523
  9. Nuovo J, Melnikow J, Willan AR, Chan BK. Treatment outcomes for squamous intraepithelial lesions. Int J Gynaecol Obstet. 2000;68:25–33
  10. Kalliala I, Nieminen P, Dyba T, Pukkala E, Anttila A. Cancer free survival after CIN treatment: comparisons of treatment methods and histology. Gynecol Oncol. 2007;105:228–233
  11. Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118:2048–2055
  12. El-Bastawissi AY, Becker TM, Daling JR. Effect of cervical carcinoma in situ and its management on pregnancy outcome. Obstet Gynecol. 1999;93:207–212
  13. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367:489–498
  14. Samson SL, Bentley JR, Fahey TJ, McKay DJ, Gill GH. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol. 2005;105:325–332
  15. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA. 2004;291:2100–2106
  16. Bruinsma F, Lumley J, Tan J, Quinn M. Precancerous changes in the cervix and risk of subsequent preterm birth. BJOG. 2006;
  17. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol. 2007;109:309–313
  18. Bell MC, Alvarez RD. Chemoprevention and vaccines: a review of the nonsurgical options for the treatment of cervical dysplasia. Int J Gynecol Cancer. 2005;15:4–12
  19. Stern PL. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. J Clin Virol. 2005;32(Suppl 1):S72–S81
  20. Persad VL, Pierotic MA, Guijon FB. Management of cervical neoplasia: a 13-year experience with cryotherapy and laser. J Low Genit Tract Dis. 2001;5:199–203
  21. Ueda M, Ueki K, Kanemura M, et al. Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. Gynecol Oncol. 2006;101:143–146
  22. van Hamont D, van Ham MA, Struik-van der Zanden PH, et al. Long-term follow-up after large-loop excision of the transformation zone: evaluation of 22 years treatment of high-grade cervical intraepithelial neoplasia. Int J Gynecol Cancer. 2006;16:615–619
  23. Paraskevaidis E, Arbyn M, Sotiriadis A, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2004;30:205–211
  24. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ. 2005;331:1183–1185
  25. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004;100:1035–1044
  26. Bornstein J, Schwartz J, Perri A, Harroch J, Zarfati D. Tools for post LEEP surveillance. Obstet Gynecol Surv. 2004;59:663–668
  27. Zielinski GD, Bais AG, Helmerhorst TJ, et al. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv. 2004;59:543–553
  28. SEER Cancer Statistics Review 1975-2003. Bethesda, MD: National Institutes of Health; 2006;
  29. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364:1678–1683
  30. Economos K, Perez Veridiano N, Delke I, Collado ML, Tancer ML. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol. 1993;81:915–918
  31. Yost NP, Santoso JT, McIntire DD, Iliya FA. Postpartum regression rates of antepartum cervical intraepithelial neoplasia II and III lesions. Obstet Gynecol. 1999;93:359–362
  32. Connor JP. Noninvasive cervical cancer complicating pregnancy. Obstet Gynecol Clin North Am. 1998;25:331–342
  33. Wright TC, Cox JT, Massad LS, Carlson J, Twiggs LB, Wilkinson EJ. 2001 consensus guidelines for the management of women with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2003;189:295–304
  34. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA. 2001;285:1500–1505
  35. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1157–1164
  36. Wright TC. Pathology of HPV infection at the cytologic and histologic levels: basis for a 2-tiered morphologic classification system. Chapter 3. Int J Gynaecol Obstet. 2006;94(Suppl 1):S22–S31
  37. Schlecht NF, Platt RW, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336–1343
  38. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al. Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet. 2001;358:1782–1783
  39. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188:1406–1412
  40. Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol. 2001;82:516–522
  41. Alvarez RD, Wright TC. Effective cervical neoplasia detection with a novel optical detection system: A randomized trial. Gynecol Oncol. 2007;104:281–289
  42. Dunn TS, Burke M, Shwayder J. A “see and treat” management for high-grade squamous intraepithelial lesion pap smears. J Low Genit Tract Dis. 2003;7:104–106
  43. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998;92:727–735
  44. Robertson AJ, Anderson JM, Beck JS, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989;42:231–238
  45. Mitchell MF, Tortolero-Luna G, Wright T, et al. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr. 1996;21:17–25
  46. Andersen ES, Nielsen K. Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. Gynecol Oncol. 2002;86:365–369
  47. Kennedy AW, Biscotti CV. Further study of the management of cervical adenocarcinoma in situ. Gynecol Oncol. 2002;86:361–364
  48. Krivak TC, Rose GS, McBroom JW, Carlson JW, Winter WE, Kost ER. Cervical adenocarcinoma in situ: a systematic review of therapeutic options and predictors of persistent or recurrent disease. Obstet Gynecol Surv. 2001;56:567–575
  49. Soutter WP, Haidopoulos D, Gornall RJ, et al. Is conservative treatment for adenocarcinoma in situ of the cervix safe?. BJOG. 2001;108:1184–1189
  50. Azodi M, Chambers SK, Rutherford TJ, Kohorn EI, Schwartz PE, Chambers JT. Adenocarcinoma in situ of the cervix: management and outcome. Gynecol Oncol. 1999;73:348–353
  51. Lea JS, Shin CH, Sheets EE, et al. Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ. Gynecol Oncol. 2002;87:129–132
  52. Hwang DM, Lickrish GM, Chapman W, Colgan TJ. Long-term surveillance is required for all women treated for cervical adenocarcinoma in situ. J Low Genit Tract Dis. 2004;8:125–131
  53. Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol. 2000;79:6–10
  54. McHale MT, Le TD, Burger RA, Gu M, Rutgers JL, Monk BJ. Fertility sparing treatment for in situ and early invasive adenocarcinoma of the cervix. Obstet Gynecol. 2001;98:726–731
  55. Bryson P, Stulberg R, Shepherd L, McLelland K, Jeffrey J. Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS?. Gynecol Oncol. 2004;93:465–468

PII: S0002-9378(07)00933-7

doi: 10.1016/j.ajog.2007.07.050

American Journal of Obstetrics & Gynecology
Volume 197, Issue 4 , Pages 340-345 , October 2007

Article Tools